ADME/Tox Research

Products

Metabolism Products

Drug metabolism plays a critical role in the toxicity, efficacy or detoxification of a drug compound. Understanding how a drug compounds' enzymatic metabolic pathways and metabolic rates influence its clearance, metabolite concentration, and potential drug-drug interactions is a critical component to developing safe and effective drugs.

BD Biosciences extensive portfolio of products and services to support the characterization of drug metabolism and drug-drug interactions include: recombinant drug metabolizing enzymes, human- and animal-derived hepatocytes and tissue fractions, antibodies, chemical substrates, metabolites and inhibitors needed to perform metabolic studies.

NEW! BD UltraPool HLM 150

The BD UltraPool™ HLM 150 is the first commercially available large donor pool of 150 donors statistically modeled to provide researchers with a high degree of lot-to-lot consistency for CYP and UGT enzyme activity, and to naturally represent the “average patient” and known CYP polymorphisms.

BD UltraPool HLM 150 pool is statistically modeled so that lot-to-lot variability represented as coefficient of variation (CV) is <10% (mean) for the more variable CYP enzyme (CYP2C19), and <5% (mean) for the key drug metabolizing CYPs (CYP1A2, CYP2C9, CYP2D6 and CYP3A4). This lot-to-lot consistency is critical for researchers to achieve data consistency for metabolic stability, CYP inhibition and reaction phenotyping assays year after year with multiple HLM lots.

Learn more »

Antibodies Against Drug Metabolizing Enzymes

BD Supersomes Recombinant Drug Metabolizing Enzymes and Controls

Enzyme Substrates, Inhibitors, Metabolite Standards, Cofactors and Buffers

Lymphoblast Expressed Enzymes

Primary Hepatocytes

Tissue Fractions



For Research Use Only. Not for use in diagnostic or therapeutic procedures.